Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | BOK |
| Gene Name: | BOK |
| Protein Full Name: | Bcl-2-related ovarian killer protein |
| Alias: | BCL2L9; Bcl-2-like protein 9; BCL2-related ovarian killer; BOKL; Hbok; MGC4631 |
| Mass (Da): | 23262 |
| Number AA: | 212 |
| UniProt ID: | Q9UMX3 |
| Locus ID: | 666 |
| COSMIC ID: | BOK |
| Gene location on chromosome: | 2q37.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBIT |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 0.1 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | As part of the Bcl-2 family, BOK may play a role in apoptosis by activating caspases following p53 signalling. Evidence also suggests it may play a role in caspase-independent apoptosis by promoting the release of mitochondrial pro-apoptotic factors into the cytosol. Overexpression of BOK induces apoptosis that seemingly cannot be inhibited by Bcl-2 or Bcl-XL. |